Director at ClearPoint Neuro (NASDAQ: CLPT) receives 222-share stock grant

Rhea-AI Filing Summary

Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro director Timothy T. Richards received 222 shares of Common Stock as compensation. The shares were granted on June 30, 2026 under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan.

The shares were valued at a price of $17.84 per share, matching the closing price of ClearPoint Neuro’s stock on June 30, 2026. Following this award, Richards directly holds 87,544 shares of ClearPoint Neuro common stock, indicating this was a routine, small incremental grant rather than a large new position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Richards Timothy T.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	222	$17.84	$4K

Holdings After Transaction: Common Stock — 87,544 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 222 shares Grant price: $17.84 per share Shares owned after transaction: 87,544 shares

3 metrics

Shares granted 222 shares Common Stock award to director on June 30, 2026

Grant price $17.84 per share Closing price on June 30, 2026 used for share issuance

Shares owned after transaction 87,544 shares Director Timothy T. Richards’ direct CLPT holdings post-grant

Key Terms

Seventh Amended and Restated 2013 Incentive Compensation Plan, Non-Employee Director Compensation Plan, Common Stock, Grant, award, or other acquisition

4 terms

Seventh Amended and Restated 2013 Incentive Compensation Plan financial

"These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan"

Non-Employee Director Compensation Plan financial

"in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan"

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 08:05 PM Accepted by SEC EDGAR 07/06/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richards Timothy T.

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		222	A	$17.84(1)	87,544	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2026.

	/s/ Danilo D'Alessandro, by Power of Attorney for Timothy T. Richards	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Timothy T. Richards?

ClearPoint Neuro reported that director Timothy T. Richards received 222 shares of common stock as a grant. The award was issued as payment of director fees under the company’s plans at the June 30, 2026 closing stock price.

Was the CLPT insider transaction a purchase or a compensation grant?

The CLPT insider transaction was a compensation grant, not an open-market purchase. Richards received 222 shares under the company’s incentive and non-employee director compensation plans in lieu of cash fees, at the June 30, 2026 closing stock price.

At what price were the 222 CLPT shares granted to Timothy T. Richards?

The 222 shares were valued at $17.84 per share, equal to ClearPoint Neuro’s June 30, 2026 closing price. This price was used to determine the number of shares issued in payment of director fees owed to Richards.

How many ClearPoint Neuro (CLPT) shares does Timothy T. Richards hold after this grant?

After receiving the 222-share grant, Timothy T. Richards directly holds 87,544 shares of ClearPoint Neuro common stock. This filing shows his updated ownership position following the director fee payment in stock rather than cash.

Which plans governed the CLPT share grant to director Timothy T. Richards?

The grant was made under ClearPoint Neuro’s Seventh Amended and Restated 2013 Incentive Compensation Plan. It served as payment for fees owed under the company’s Non-Employee Director Compensation Plan, as amended and restated.